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Abstract A mathematical modeling of Hepatitis C Virus (HCV) dynamics has
been presented in this paper. The proposed model, which involves four coupled
ordinary differential equations, describes the interaction of target cells (hepato-
cytes), infected cells, infectious virions and non-infectious virions. The model takes
into consideration the addition of ribavirin to interferon therapy and explains the
dynamics regarding biphasic and triphasic decline of viral load in the model. A
critical drug efficiency parameter has been defined and it is shown that for efficien-
cies above this critical value, HCV is eradicated whereas for efficiencies lower this
critical value, a new steady state for infectious virions is reached, which is lower
than the previous steady state.
Keywords Hepatitis C Virus (HCV) · Target cells · Infected cells · Infectious
virions · Noninfectious Virions · Interferon · Ribavirin.
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1 Introduction
Hepatitis C is an infectious viral disease caused by Hepatitis C Virus (HCV) and
its infection route is via the blood. HCV was first identified in 1989, when the
expression of cDNAs obtained from the blood plasma of a chimpanzee was in-
duced with hepatitis non-A, non B and was screened with convalescent serum [1].
It should be noted that HCV was the first virus to be discovered by molecular
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2biological method and not by previously used virological methods. Accordingly to
WHO, individuals between 200 to 300 millions worldwide are currently infected
with HCV [2]. With the discovery of HCV virus, a new dimension on the treatment
and prevention of liver diseases evolved [3]. Previously, patients who were thought
to be suffering from hepatitis non-A or non-B or even alcoholic liver disease, actu-
ally have hepatitis C. As the dynamics of hepatitis C virus was understood with
time, it becomes clear that the disease is a major threat for hepatocellular carci-
noma.
Since the identification of the hepatitis C virus, great efforts have been made
to counter-attack it with an antiviral therapy. As a crucial mediator of the innate
antiviral immune response, interferon-α (IFN-α) was a natural choice for treat-
ment [4]. With IFN-α therapy, there was a rapid decline in HCV-RNA levels in
serum but it can achieve only moderate success. With IFN-α monotherapy, that
is, therapy will IFN-α alone do not achieve clearance of HCV in half of the infected
individuals suffering from chronic hepatitis C. A major break through came with
the addition of broad-spectrum antiviral agent ribavirin to IFN-α treatment. With
combination of pegyleted interferon and ribavirin, a sustained response rates of
54-56% can be achieved [7,8,9]. But this combined therapy is expensive and have
some side effects. Therefore, there is a need for more effective and better tolerated
therapies for hepatitis C. However, due to difficulty of developing new, potent,
specific agents against HCV, this combined therapy of pegylated interferon and
ribavirin is going to remain as the sole therapy in the near future. With more
better understanding of the mechanism of interferon and ribavirin together with
improvement in dosing and dose regimen, it is expected that there is going to be
substantial improvement in the response rates of the patients suffering from hep-
atitis C.
Some patients suffering from hepatitis C naturally clear the virus infection
without any medical intervention but mostly (55-85%) cannot do that and de-
velop chronic HCV infection [5]. In the standard protocol for the treatment of
hepatitis C, a patient is given weekly injection of IFN and take ribavirin pills daily
for the period of treatment [6]. If after six months of therapy, a patient does not
show any trace of hepatitis C viral load, then the patient is said to have achieved
sustained virological response (SVR), implying clinically cured. The aim of this
combined therapy is to reduce the viral load to a minimum, so that a patient
achieves SVR. If the therapy fails, a patient fails to achieve SVR and suffers from
chronic hepatitis C. It should be noted that in hepatitis C patients, the rate of
achievements of SVR depends on the genotype of the particular infecting virus.
Genotypes 1 and 4 are usually treated for 48 weeks whereas genotypes 2 and 3 are
done for 24 weeks with lesser doses of ribavirin [10]. It is observed that 46% of the
patients with genotype 1 have achieved SVR under this treatment whereas SVR
rates of 76-82% are observed in patients with HCV genotypes 2 or 3 [11].
To understand the dynamics of hepatitis C, specially, to determine the effi-
ciency of IFN-α as monotherapy and also in combination with ribavirin, mathe-
matical models have been used extensively, which have provided insights into the
pathogenesis of HCV in vivo [12,13,15,16,17]. Other than suggesting predomi-
nated mechanism(s) of drug action, the models have been successful in explaining
3the confounding patterns of viral load changes in HCV infected patients undergo-
ing therapy.
Neumann et. al [12], used the basic model of viral dynamics to HCV, which
assumes a simplified view of HCV infection by taking into account of IFN-α
monotherapy. The model consists of three populations, namely, uninfected hep-
atocytes (the target cell), productively infected hepatocytes and free HCV virions
and describes the response to interferon therapy. Though the basic model by Neu-
mann [12] provides insights into the HCV dynamics in vivo but it fails to predict
the long term response rates observed during combination therapy as it ignores
the influence of ribavirin. Dixit et. al. [13] made an advancement in the basic
model by taking into account the role of ribavirin action along with interferon.
The dynamics of model suggests that ribavirin has very little role to play during
the first phase decline induced by interferon, as ribavirin does not alter the viral
production. However, ribavirin enhances the second phase slope when interferon
effectiveness is small, which is in close agreement with experiments [14] .
One of the drawback of the model by Dixit et. al. [13] is that non-responders
and patients with triphasic decay patterns are not studied and is restricted to
biphasic responses only. A modified model, which include the proliferation of un-
infected and infected cells driven by liver homeostatic mechanisms was studied by
Dahari et. al. [15,16]. The model predicts the triphasic decline and succeeds in
explaining the origins of non-response. In a recent study, Chakrabarty and Joshi
[17] presented a model where they used deterministic control theory to obtain an
optimal treatment strategy using interferon and ribavirin. The optimal treatment
which they obtained succeeded in reducing the levels of viral load and at the same
time keeping the side effects of the drug to a minimal. Swati DebRoy et al. [18]
discussed one of the common and life threatening side effect, namely, hemolytic
anemia, of hepatitis C infection. They used an extension and modification of Neu-
mann’s model [12] to study the effect of combination therapy in the light of anemia
and succeeded in providing a quantification of the amount of drug a body can tol-
erate without succumbing to hemolytic anemia.
In this paper, a mathematical model is proposed depicting the behavior of hep-
atitis C virus. The idea is to capture the dynamics of the model due to combined
effect of antiviral drug therapy: interferon and ribavirin. In section 2, formulation
of the model based of the schematic diagram has been discussed. Qualitative anal-
ysis of the model has been shown in section 3, which includes determination of
equilibrium points, positivity and boundedness of the system, local stability anal-
ysis and persistence of the system. Global stability analysis about the endemic
equilibrium point has been shown in section 4. Numerical results, capturing the
dynamics of HCV are discussed in section 5. The paper ends with a discussion.
2 Mathematical Model
Adaptive immune responses mediated by T cells are essential in the control of
HCV and viral clearance. Recent studies in which memory CD4+ and CD8+ T
cells were depleted have confirmed the critical role of these cells in controlling HCV
4infections [19]. Hence, these cells are the target cells (or hepatocytes). Once in-
fected with HCV, these target cells becomes infected hepatocytes, which replicates
the hepatitis C virus. The replicated viruses may be infectious or non-infectious,
depending on the effectiveness of the drug(s) therapy. Figure 1 gives the schematic
representation of the above biological scenario. The proposed model is given by
the following system of coupled ordinary differential equations:
dT
dt
= s+ rT
(
1− T + I
k
)
− d1T − (1− cη1)αVIT (1)
dI
dt
= (1− cη1)αVIT − d2I (2)
dVI
dt
=
(
1− ηr + η1
2
)
βI − d3VI (3)
dVNI
dt
=
(
ηr + η1
2
)
βI − d3VNI (4)
The first equation gives the dynamics of the target cells, that is, hepatocytes. They
are produced from a source at a constant rate s and at the same time, their growth
is augmented by a logistic term with an intrinsic growth rate r and carrying capac-
ity k. The hepatocytes die naturally at a rate d1. The logistic term rT
(
1− T+I
k
)
is
more realistic in the sense that it incorporates total hepatocytes, both non-infected
and infected ones. Here η1 denotes the effectiveness (or efficacy) of interferon in
blocking the release of new virions, cη1 is fraction of the efficacy (0 < c < 1) and
hence (1−cη1) gives the ineffectiveness of interferon, which fails to stop the target
cells getting infected. The number of cells which gets infected is proportional to the
number of infection virions and available target cells (hepatocytes) with a propor-
tionality constant α, which explains the term (1−cη1)αVIT in (1) and (2). Infected
cells die at a rate d2. Equations (3) and (4) give the dynamics of virions, namely,
the infected and non infected ones. The term
(
ηr+η1
2
)
is the effectiveness of com-
bined effect of interferon and ribavirin
(
0 < ηr < 1, 0 < η1 < 1⇒ 0 < ηr+η12 < 1
)
and hence
(
1− ηr+η12
)
is the ineffectiveness of the combined effect, which leads
to the growth of the infection virions, proportional to the number of infected
cells (I) with proportionality constant β (infection rate). This explain the term(
1− ηr+η12
)
βI in (3). The infectious virions die at a rate d3. In (4), the combined
effect of interferon and ribavirin results in virions (VNI), which are non-infectious
in nature and also die at a rate d3. System (1-4) has to be analyzed with the
following initial conditions: T (0) > 0, I(0) > 0, VI(0) > 0, VNI(0) > 0. All system
parameters are positive.
3 Qualitative Analysis of the model
3.1 Positivity and Boundedness
Theorem 1 The solutions of the system (1-4) are positive for all t > 0.
Proof Let (T (t), I(t), VI(t), VNI(t)) be a solution of system (1-4). Consider for
some time t1 > 0, T (t1) = 0 and if t1 be the first such time, then
dT (t1)
dt
≤ 0. But
from (1), dT (t1)
dt
= s > 0, which is a contradiction. Therefore, T (t) > 0, for all
5t > 0.
It is again observed that I(t) > 0 for t ≥ 0 as
dI
dt
≥ −d2I ⇒ I(t) = I(0)e−d2t (5)
(6)
Similarly, (3) and (4) gives
VI =
(
1− ηr + η1
2
)
βe
−d3t
t∫
0
I(s)e−d3sds > 0 (7)
VNI =
(
ηr + η1
2
)
βe
−d3t
t∫
0
I(s)e−d3sds > 0, (8)
Therefore, it is concluded that (T (t), I(t), VI(t), VNI(t)) > 0 for all t ≥ 0.
Theorem 2 The solutions of the system (1-4) are bounded.
Proof Let (T (t), I(t), VI(t), VNI(t)) be any solution of system. Let
ρ(t) = T (t) + I(t) + VI(t) + VNI(t) (9)
The derivative of ρ(t) along the positive solutions of system 1 is given by
dρ
dt
= s+ rT − rT
2
k
− rTI
k
− d1T − d2I + βI − d3VI − d3VNI
≤ s+ rT − rT
2
k
− d1T − d2I + βI − d3VI − d3VNI
≤ s+ rT − rT
2
k
−Aρ(t)
= −Aρ(t) + (s+ rk
4
)−
(√
rT√
k
−
√
rk
2
)2
≤ −Aρ(t) + (s+ rk
4
) (10)
where A = min[d1, (d2 − β), d3] and d2 > β. It follows from (10) that
lim
t→+∞
sup ρ(t) ≤ (s+ rk
4
) = M∗.
Therefore, there exist positive constants M > M∗ and T1 > 0 such that if t ≥
T1, ρ(t) < M. This completes the proof.
63.2 Equilibria
System (1-4) has the following non-negative equilibrium points:
(a) E0(T̂ , 0, 0, 0) where T̂ =
k
2r
[
(r − d1) +
√
(r − d1)2 + 4rsk
]
, where r > d1. We
assume s ≤ kd1 so that the model is physiologically realistic, that is, T̂ ≤ k.
(b) E∗(T
∗, I∗, V ∗I , V
∗
NI ), where,
T
∗ =
d2d3
(1− cη1)
(
1− ηr+η12
)
αβ
,
I
∗ =
srRˆ2 + (r − d1)2k(Rˆ− 1)
rRˆ[d2Rˆ+ (r − d1)]
,
V
∗
I =
(
1− ηr+η12
)
βI∗
d3
,
V
∗
NI =
(
ηr+η1
2
)
βI∗
d3
.
Here, Rˆ, the controlled reproductive number (CRN) [18] is defined as Rˆ =
R0k
T̂
(
r−d1
r
)
and the basic reproductive number of the model is calculated as R0 =
T̂
T∗
. It may be noted that E∗ exists even when Rˆ < 1, provided, srRˆ
2 + (r −
d1)
2k(Rˆ− 1) > 0. However, it always exists for Rˆ > 1
3.3 Local Stability Analysis
Theorem 3 The disease free equilibrium point E0 is locally asymptotically stable
if R0 < 1 and unstable if R0 > 1.
Proof The variational matrix for the equilibrium point E0 is
V0 =

(r − d1)− 2rT̂k − rT̂k −(1− cη1)αT̂ 0
0 −d2 (1− cη1)αT̂ 0
0
(
1− ηr+η12
)
β −d3 0
0
(
ηr+η1
2
)
β 0 −d3

The corresponding characteristic equation is(
λ− (r − d1) + 2rT̂
k
)
(λ+ d3)(λ
2 − Cλ+D) = 0 (11)
where C = −(d2 + d3) and D = [d2d3 − 12 (1 − cη1)(2 − ηr − η1)αβT̂ ]. For local
asymptotic stability, all roots of the characteristic equation must be negative or
have negative real parts. Since, the linear factor gives negative eigenvalues and
C < 0, for stability D must be positive, that is, T̂
T∗
< 1. Therefore, the uninfected
steady state E0 is stable if R0 < 1 and unstable if R0 > 1.
Theorem 4 The endemic equilibrium point E∗ is locally asymptotically stable if
1 < R̂ < 3.
7Proof The variational matrix for the equilibrium point E∗ is
V2 =

− srRˆ
k(r−d1)
− (r−d1)
Rˆ
− (r−d1)
Rˆ
− (1−cη1)αk(r−d1)
rRˆ
0
d2[
srRˆ2+k(r−d1)
2(Rˆ−1)
(r−d1)k(d2Rˆ+(r−d1))
] −d2 (1−cη1)αk(r−d1)
rRˆ
0
0
(
1− ηr+η12
)
β −d3 0
0
(
ηr+η1
2
)
β 0 −d3

The characteristic equation is obtained as
(λ1 + d3)(λ
3 + A1λ
2 +A2λ+A3) = 0 (12)
where
A1 = d2 + d3 +
(r − d1)
Rˆ
+
rRˆs
(r − d1)k
A2 = (d2 + d3)
[
(r − d1)
Rˆ
+
rRˆs
(r − d1)k
]
+
d2
((r− d1) + d2Rˆ)
[
(r − d1)2
(
1− 1
Rˆ
)
+
rRˆs
k
]
A3 = d2d3
[
(r − d1)
(
1− 1
Rˆ
)
+
rRˆs
(r − d1)k
]
A1A2 −A3 =
(
3
Rˆ
− 1
)
d2d3r + (d
2
2 + d
2
3)
(r − d1)
Rˆ
+ (d2 + d3)
[
(r − d1)2
Rˆ2
+
2rs
k
+
r2Rˆ2s2
(r − d1)2(k)2
]
+
d2(r − d1)
(r − d1) + d2Rˆ
[
(r − d1)d2 + (r − d1)d3 + (r − d1)
2
Rˆ
](
1− 1
Rˆ
)
+ d2(d2 + d3)
rRˆs
k
[
1
(r − d1) +
1
(r − d1) + d2Rˆ
]
+
rRˆsd23
(r − d1)k
+
d2rRˆs
k((r − d1) + d2Rˆ)
[
(r − d1) + rRˆs
k(r − d1)
]
According to Routh-Hurwitz criterion, the necessary and sufficient conditions
for all the roots of cubic equation (12) to have negative real parts are A1 > 0, A2 >
0, A3 > 0 and A1A2 −A3 > 0. Clearly, A1 > 0. Now, A2 > 0 and A3 > 0 if Rˆ > 1
and A1A2 − A3 > 0 provided 1 < Rˆ < 3. Thus, the endemic equilibrium point
E∗(T
∗, I∗, V ∗I , V
∗
NI ) is locally asymptotically stable if the controlled reproductive
number Rˆ satisfies the condition. It should be noted that the endemic equilibrium
point E∗ will be unstable whenever it exists for Rˆ < 1.
3.4 Critical drug efficacy
In system (1), the effectiveness of interferon and ribavirin are given by the terms
(1 − cη1) and
(
1− ηr+η12
)
. Here, these terms are combined into a single term as
(1−cη1)
(
1− ηr+η12
)
= 1−η, where η represents the overall drug efficiency. Clearly,
η1 = ηr = 0, that is, drug efficiency is zero before treatment and 0 < η1 < 1, 0 <
8ηr < 1 during antiviral therapy. The stability criteria for uninfected steady state
(D > 0) is
d2d3 − 1
2
(1− cη1)(2− ηr − η1)αβT̂ > 0,where, T̂ = k
2r
[
(r − d1) +
√
(r − d1)2 + 4rs
k
]
⇒ (1− cη1)
(
1− ηr + η1
2
)
<
d2d3
αβT̂
⇒ 1− η < 2rd2d3
αβ[(r − d1)k +
√
(r − d1)2k2 + 4rsk)]
This clearly indicates that there exists a point that acts as a point of separation
between the region of stability for uninfected steady state and the region of stability
for infected steady state. This point can be termed as a transcritical bifurcation
point, which is given by
1− η = 2rd2d3
αβ[(r − d1)k +
√
(r − d1)2k2 + 4rsk)]
Accordingly, the critical drug efficacy is defined as
ηε = 1− 2rd2d3
αβ[(r − d1)k +
√
(r − d1)2k2 + 4rsk)]
= 1− T
∗
0
T̂
where T ∗0 =
d2d3
αβ
is the number of uninfected hepatocytes in an infected person
before treatment (obtained by putting η1 = ηr = 0 in T
∗) and T̂ is the total
number of hepatocytes in an uninfected individual.
During antiviral therapy, if η > ηε, the drug therapy is successful and the
viral load can be eradicated. On the other hand, if η < ηε, the viral load and the
infected cells converge to a new steady state with lower values.
3.5 Permanence of the system
Definition 1 A system is said to be permanent if there exist positive constants
δ,∆, with 0 < δ ≤ ∆ such that
min
{
lim
x→+∞
inf T (t), lim
x→+∞
inf I(t), lim
x→+∞
inf VI(t), lim
x→+∞
inf VNI (t)
}
≥ δ,
max
{
lim
x→+∞
supT (t), lim
x→+∞
sup I(t), lim
x→+∞
supVI(t), lim
x→+∞
supVNI(t)
}
≤ ∆
for all solutions of the system.
Theorem 5 The system (1-4) is permanent if (r − d1)− (1− cη1)αVI − rIk > 0.
9Proof Since all the state variables are bounded, it is obvious that I(t) ≤ M∗∗.
Then (1) can be rewritten as
dT
dt
= s+ rT
(
1− T + I
k
)
− d1T − (1− cη1)αVIT ≤ s+ rT − rT
2
k
= s−
(√
rT√
k
−
√
rk
2
)2
+
rk
4
≤
(
s+
rk
4
)
.
⇒ lim
t→+∞
supT (t) ≤
(
s+
rk
4
)
= T (say).
(3) and (4) gives,
d(VI + VNI)
dt
= βI − d3(VI + VNI ) ≤ d3
(
βM∗∗
d3
− (VI + VNI)
)
.
Hence,
lim
t→+∞
sup(VI + VNI) ≤ βM
∗∗
d3
.
Therefore,
lim
t→+∞
supVI ≤ βM
∗∗
d3
= VI (say)
and
lim
t→+∞
supVNI ≤ βM
∗∗
d3
= VNI (say).
From (2) we get,
dI
dt
= (1− cη1)αVIT − d2I ≤ (1− cη1)VIαT − d2I = d2
[
(1− cη1)VIαT
d2
− I
]
.
So
lim
t→+∞
sup I(t) ≤ (1− cη1)VIαT
d2
= I.
From the definition of limit superior, again for every ǫ > 0, there exist a time T2
such that I(t) ≥ (I − ǫ) for t ≥ T2.
Again from (3) we get,
dVI
dt
=
(
2− η1 − ηr
2
)
βI − d3VI ≥
(
2− η1 − ηr
2
)
β(I − ǫ)− d3VI
= d3
[
(2− η1 − ηr)β(I − ǫ)
2d3
− VI
]
.
Using differential equality we have,
lim
t→+∞
inf VI(t) ≥ (2− η1 − ηr)β(I − ǫ)
2d3
,
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Since ǫ > 0 is arbitrarily small, we have
lim
t→+∞
inf VI(t) ≥ (2− η1 − ηr)βI
2d3
= VI .
From (4) we get,
dVNI
dt
=
(
η1 + ηr
2
)
βI − d3VNI ≥
(
η1 − ηr
2
)
β(I − ǫ)− d3VNI
= d3
[
(η1 + ηr)β(I − ǫ)
2d3
− VNI
]
.
Using differential equality we have,
lim
t→+∞
inf VNI(t) ≥ (η1 + ηr)β(I − ǫ)
2d3
,
Since ǫ > 0 is arbitrarily small, we have
lim
t→+∞
inf VNI(t) ≥ (η1 + ηr)βI
2d3
= VNI .
Again from (1),
dT
dt
= s+ rT
(
1− T + I
k
)
− d1T − (1− cη1)αVIT
≥ T
[
(r − d1)− rI
k
− (1− cη1)αVI − rT
k
]
≥ T
[
(r − d1)− rI
k
− (1− cη1)αVI − rT
k
]
=
r
k
T
[
((r − d1)− (1− cη1)αVI − rI
k
)
k
r
− T
]
.
Therefore,
lim
t→+∞
inf T (t) ≥
[
(r − d1)− (1− cη1)αVI − rI
k
]
= T .
if [
(r − d1)− (1− cη1)αVI − rI
k
]
> 0. (13)
From (2) we get,
dI
dt
= (1− cη1)αVIT − d2I ≥ (1− cη1)αVIT − d2I = d2[
(1− cη1)αVIT
d2
− I].
which implies
lim
t→+∞
inf I(t) ≥ (1− cη1)αVIT
d2
= I.
Therefore, from condition (13) we conclude that T > 0, which ensures that I >
0, VI > 0, VNI > 0. This completes the proof of Theorem.
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4 Global Stability of the endemic equilibrium point E∗
To study the global stability of endemic equilibrium point E∗, the geometric ap-
proach of Li and Muldowney [20], which guarantees the global stability of endemic
equilibrium point by obtaining simple sufficient conditions, has been used.
Theorem 6 Let x→ f(x) ∈ R4 be a C1 function (class of functions whose deriva-
tives are continuous) for x in a simply connected domain D ⊂ R4, where
x =
 TI
VI
VNI
 and f(x) =

s+ rT
(
1− T+I
k
)− d1T − (1− cη1)αVIT
(1− cη1)αVIT − d2I(
1− ηr+η12
)
βI − d3VI(
ηr+η1
2
)
βI − d3VNI

Consider the system of differential equations x˙ = f(x) subject to the initial con-
dition (T0, I0, VI0, VNI0)
T = x0(say) Let x(t, x0) be a solution of the system. The
system (1-4) has a unique endemic equilibrium point E∗ in D and there exits a
compact absorbing set K ⊂ D. It is further assumed that the system (1-4) satisfies
Bendixson criterion [20], that is robust under C1 local perturbations of f at all
non-equilibrium non-wandering points of the system. Let x → M(x) be a 6 × 6
matrix valued function that is C1 for x ∈ D. It is also assumed that M−1(x) exists
and is continuous for x ∈ K. Then the endemic unique equilibrium point E∗ is
globally stable in D if
q¯2 = lim
t→∞
sup sup
x0ǫk
1
t
∫ t
0
µ(B(x(s, x0)))ds < 0 (14)
where B = MfM
−1 + M ∂f
[2]
∂x
M−1, the value Mf is obtained by replacing each
entry mij in M by its directional derivative in the direction of f,∇m∗ijf and µ(B)
is the Lozinski˘i measure of B with respect to a vector norm |.| in R4, defined by
[21],
µ(B) = lim
h→0+
|I + hB| − 1
h
(15)
Proof Since permanence with respect to a set of variables implies persistence with
respect to the same set of variables, it can be concluded that the system (1-4) is
persistent. Clearly, the system (1-4) has a unique endemic equilibrium point E∗ in
D and the persistence of the system, together with the boundedness of solutions,
implies the existence of a compact absorbing set K ⊂ D [22].
The Jacobian matrix J of the system (1-4) is
J =

− rT
k
− s
T
− rT
k
−(1− cη1)αT 0
(1− cη1)αVI −d2 (1− cη1)αT 0
0 ( 2−ηr−η12 )β −d3 0
0 (ηr+η12 )β 0 −d3

and the corresponding associated second compound matrix J [2] (for detailed dis-
cussion of compound matrices, their properties and their relations to differential
equations, the readers are referred to [23] and [24]) is given by
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J [2] =

a11 (1− cη1)αT 0 (1− cη1)αT 0 0
( 2−ηr−η12 )β a22 0 − rTk 0 0
(ηr+η12 )β 0 a22 0 − rTk −(1− cη1)αT
0 (1− cη1)αVI 0 −d2 − d3 0 0
0 0 (1− cη1)αVI 0 −d2 − d3 (1− cη1)αT
0 0 0 −(ηr+η12 )β ( 2−ηr−η12 )β −2d3

Set the function Q = Q(T, I, VI , VNI) ≡ diag
(
1, 1, 1, 1, I
VI
, I
VI
)
, then
QfQ
−1 = diag
(
0, 0, 0, 0, I˙
I
− V˙I
VI
, I˙
I
− V˙I
VI
)
and B = QfQ
−1 +QJ [2]Q−1
Therefore,
B =

a11 (1− cη1)αT 0 (1− cη1)αT 0 0
( 2−ηr−η12 )β a22 0 − rTk 0 0
(ηr+η12 )β 0 a22 0 − rTVIIk − (1−cη1)αTVII
0 (1− cη1)αVI 0 −d2 − d3 0 0
0 0 (1− cη1)αI 0 a55 (1− cη1)αT
0 0 0 −(ηr+η12 )βIVI (
2−ηr−η1
2 )β a66

≡
[
B11 B12
B21 B22
]
.
where
a11 = −rT
k
− s
T
− d2,
a22 = −rT
k
− s
T
− d3,
a55 = −d2 − d3 + I˙
I
− V˙I
VI
,
a66 = −2d3 + I˙
I
− V˙I
VI
,
B11 = [a11] = [− rTk − sT − d2], B12 =
[
(1− cη1)αT 0 (1− cη1)αT 0 0
]
,
B21 = [(
2−ηr−η1
2 )β, (
ηr+η1
2 )β, 0, 0, 0]
T and
B22 =

a22 0 − rTk 0 0
0 a22 0 − rTVIIk − (1−cη1)αTVII
(1− cη1)αVI 0 −d2 − d3 0 0
0 (1− cη1)αI 0 a55 (1− cη1)αT
0 0 −(ηr+η12 )βIVI (
2−ηr−η1
2 )β a66
 .
We now define Lozinski˘i measure of matrix B as follows:
µ(B) ≤ max{g1, g2} (16)
where g1 = µ(B11) + ||B12|| and g2 = ||B21|| + µ(B22) (||.|| denotes the vector
norm).
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It can be shown that (see Appendix)
µ(B) ≤ I˙
I
− b (17)
where
b =
βI
VI
− β − (1− cη1)αV1 − 2(1− cη1)αT −
(
ηr + η1
2
)
2βI
VI
− max
{
−d2 +
(
2− ηr − η1
2
)
β,−d3 + (1− cη1)αT
}
(18)
for sufficiently large t. Then along each solution (T (t), I(t), VI(t), VNI(t)) such
that (T (0), I(0), VI(0), VNI(0)) ∈ E we have for t > t
1
t
∫ t
0
µ(B)ds ≤ 1
t
∫ t
0
µ(B)ds+
1
t
ln
(
I(t)
I(t)
)
−
(
t− t
t
)
η. (19)
Thus boundedness of I(t) and definition of q2 finally gives q2 < 0. The endemic
equilibrium point E∗(T
∗, I∗, V ∗I , V
∗
NI ) is globally stable.
5 Numerical Results
System (1-4) has been simulated for viral kinetics during successful antiviral treat-
ment with the parameter values taken from table 1. Fig.2 shows the kinetics of
the viral decline in patients responding to interferon, which is biphasic in nature.
During the first phase, almost all patients treated with interferon show rapid dose
dependent viral decline for about 24 to 48 hours [12,25,26]. A second phase starts
after about 48 hours where the viral decline is slow. This dynamics is well captured
in fig.2, which shows that the viral load declines to a very low level and eventually
eradicated, depending on the efficacy of interferon.
When the effectiveness of interferon is quite large, ribavirin does not have
significant impact on the second phase decline [27]. This is evident from fig.3.
Comparing fig.2 with fig.3, it is observed that both of them portray almost iden-
tical graphs though the efficacy of ribavirin in fig.2 is zero (ηr = 0) and in fig.3 is
0.3 (ηr = 0.3), confirming the fact that ribavirin fails to alter the viral load when
the efficacy of interferon is effectively large.
It has been reported that there are few patients who do not respond to ini-
tial interferon therapy and are termed as null-responders. Re-treatment of null-
responders to a standard interferon regimen shows a considerable first phase de-
cline, followed by a minor further decline during the second phase and then a
rebound of HCV is observed [28,29]. This dynamics is well portrayed in fig.4,
which corresponds to the rebound of the viral load during standard interferon
regime to the re-treatment of non-responders.
However, ribavirin enhances the second phase slope if the effectiveness of inter-
feron is significantly less that 1 (see fig.5). This interesting behavior is due to the
fact that interferon initially clears the infectious virions effectively, which results
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in the first phase decline of the viral load. Ribavirin does not have any effect on
the first phase decline as it does not alter the viral load. Also, when the effective-
ness of interferon is large, ribavirin has very little role to play as virion production
is low but when interferon effectiveness is small, ribavirin renders progeny viri-
ons non-infectious and enhances the second phase decline. This behavior has been
confirmed by experimental observations [30,31,32]. Fig.5 is able to capture this
dynamics with lower interferon efficacy and varying the effectiveness of ribavirin.
From the figure it is concluded that the patient attains sustained virological re-
sponses (SVR) during the combined drug therapy, that is, the concentration of
the viral particles in the blood falls below the detection limit during therapy and
remains undetected for 24 weeks even after the therapy is stopped. Patients who
exhibit SVR are generally cured of the HCV infection.
Several experiments have been conducted to evaluate ribavirin monotherapy
in the treatment of chronic HCV [33,34,35]. In all these experiments, no virologic
end-of-treatment-responses (ETR) were observed; either there is a minor decline
or HCV RNA level remains constant after 3-6 months of ribavirin monotherapy
compared with pretreatment values [33,34]. This dynamics is reflected in fig6.
Fig.7 shows the viral kinetics after the therapy cessation. A virus resurgence
post therapy cessation has been simulated for the system (1-4), with different
drug efficacies (η1, ηr) = ((0.4,0.6); (0.4,0.8); (0.4,0.99)) from time 0 to 14 days
and then set η1 and ηr to zero for the rest of the simulation. After 14 days, the
virus resurges to pretreatment levels within (7-7.5) days of post therapy cessation.
Thus, the model given by system (1-4), predicts resurgences to pretreatment levels
after cessation of therapy.
The triphasic decay of viral load for certain parameter values is illustrated in
fig.8. As mentioned earlier, viral production and hence viral load decreases due
to interferon action during the first phase; as a result of which, the production of
infected cells by new infections falls and the total number of cells decline. Home-
ostatic mechanisms act to restore the total number of cells by cell proliferation.
However, since the proliferation term is only with uninfected cells, homeostatic
mechanisms result predominantly in the proliferation of the uninfected cells. But
the rate at which the uninfected cells gets infected is much less than the rate at
which the immune mediated effective killing of virions continues due to interferon
effectiveness and this results in the second phase of the triphasic decline. As the
effectiveness of interferon gradually decreases, the role of ribavirin becomes pre-
dominant and results in further declining of the viral load, which explains the third
phase of the triphasic decline of the viral load (see fig.8).
As there is an increase in the influx rate of new hepatocytes(s), the triphasic
viral decay disappears and yields a biphasic decay (see fig.9). It is also to be noted
that for different drug efficacies close to 1, both the biphasic viral decay (fig.2)
and the triphasic viral decay (fig.8) is close to the death rate (d2) of infected
hepatocytes (I).
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6 Conclusion
Millions of people all over the world are infected with HCV with high levels of
mortality [36]. The models illustrating the HCV dynamics provide key insights
into the HCV pathogenesis in vivo and action mechanism of interferon and rib-
avirin [37]. To study the dynamics of hepatitis C virus, a mathematical model
comprising of four coupled ordinary differential equations has been proposed to
understand the role of ribavirin in interferon therapy. The positivity and bounded-
ness of the system has been established. The basic reproduction number (R0) and
the controlled reproduction number (R̂) of the model have been calculated. It is
observed mathematically that the local stability of the uninfected steady state de-
pends on basic reproduction number (R0) and infected steady state on controlled
reproduction number (R̂). The permanence and global stability analysis of the
model are established. A critical drug efficacy component ηc has been defined and
characterized.
Numerical simulation of system (1) shows some interesting results, which mimic
the dynamics of hepatitis C virus in patients with successful therapy with inter-
feron and ribavirin. There is a rapid decline in viral load followed by a second
slower decline (biphasic decline) until the virus becomes undetectable [12,38,39].
A triphasic decay [16] of viral load has also been observed in the model with proper
choice of interferon and ribavirin effectiveness. The critical drug efficacy parameter
leads to a point (a transcritical bifurcation point) in the model that determines
the successful antiviral therapy leading to HCV eradication or leading only to a
partial response. Thus, the HCV dynamics that the model predicts, provide some
insights on the possible mechanism for the behavior of the viral load observed in
the clinic [16]. We sincerely hope that the application of this model will give a
better understanding in the success of anti-viral therapy in HCV infection.
7 Appendix
Calculation of Lozinski˘i measure of matrix B
Lozinski˘i measure of matrix B has been defined as follows:
µ(B) ≤ max{g1, g2} (20)
where g1 = µ(B11) + ||B12|| and g2 = ||B21|| + µ(B22) (||.|| denotes the vector
norm).
It is easy to compute µ(B11) = − rTk − sT − d2, ||B12|| = (1 − cη1)αT and
||B21|| = β, then
g1 = −rT
k
− s
T
− d2 + (1− cη1)αT (21)
g2 = β + µ(B22 = C) (22)
The matrix [B22]5×5 is partitioned as B22 = C =
[
C11 C12
C21 C22
]
where C11 = [a22] = [− rTk − sT −d3], C12 =
[
0 − rT
k
0 0
]
, C21 = [0(1−cη1)αVI00]T
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and C22 =

a22 0 − rTVIIk − (1−cη1)αTVII
0 −d2 − d3 0 0
(1− cη1)αI 0 a55 (1− cη1)αT
0 −(ηr+η12 )βIVI (
2−ηr−η1
2 )β a66
.
Accordingly,
µ(C) ≤ max{g3, g4} (23)
where
g3 = µ(C11) + ||C12|| = − s
T
− d3 (24)
g4 = (1− cη1)αVI) + µ(C22) (25)
To compute µ(C22), the matrix [C22]5×5 is again partitioned as C22 = D =[
D11 D12
D21 D22
]
, whereD11 = [a22] = [− rTk − sT−d3], D12 =
[
0 − rTVI
Ik
− (1−cη1)αTVI
I
]
,
D21 = [0 (1− cη1)αT 0]T and D22 =
 −d2 − d3 0 00 a55 (1− cη1)αT
−(ηr+η12 )βIVI (
2−ηr−η1
2 )β a66

Denoting
µ(D) ≤ max{g5, g6} (26)
where g5 = µ(D11) + ||D12|| and g6 = ||D21||+ µ(D22).
We have, µ(D11) = − rTk − sT − d3,
||D12|| = TVII max
[
r
k
, (1− cη1)α
]
= TVI
I
[(1− cη1)α] as (1− cη1)α > rk , ||D21|| = (1− cη1)αT. Let
D22 = E =
[
E11 E12
E21 E22
]
, then
g5 = −rT
k
− s
T
− d3 + TVI
I
[(1− cη1)α] (27)
g6 = (1− cη1)αT + µ(D22 = E) (28)
and
E11 = [−d2 − d3], E12 =
[
0 0
]
, E21 =
[
0
−(ηr+η12 )βIVI
]
E22 =
[
a55 (1− cη1)αT
( 2−ηr−η12 )β a66
]
Again, we define Lozinski˘i measure of E as follows:
µ(E) ≤ max{g7, g8} (29)
where g7 = µ(E11) + ||E12|| and g8 = ||E21||+ µ(E22).
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We have, µ(E11) = −d2 − d3, ||E12|| = 0, ||E21|| =
(
ηr+η1
2
)
βI
VI
and
µ(E22) = max
[
a55 +
(
2− ηr − η1
2
)
β, (1− cη1)αT + a66
]
=
{
I˙
I
− V˙I
VI
− d3
}
+max
{
−d2 +
(
2− ηr − η1
2
)
β,−d3 + (1− cη1)αT
}
Therefore
g7 = −d2 − d3 (30)
g8 =
{
I˙
I
− V˙I
VI
− d3
}
+
(
ηr + η1
2
)
βI
VI
+ max
{
−d2 +
(
2− ηr − η1
2
)
β,−d3 + (1− cη1)αT
}
(31)
So, from equation (30), (31) and inequality (29), we get
µ(E) ≤
{
I˙
I
− V˙I
VI
− d3
}
+
(
ηr + η1
2
)
βI
VI
+ max
{
−d2 +
(
2− ηr − η1
2
)
β,−d3 + (1− cη1)αT
}
(32)
From (28) and (32), we obtain,
g6 ≤
{
I˙
I
− V˙I
VI
− d3
}
+ 2(1− cη1)αT +
(
ηr + η1
2
)
βI
VI
+ max
{
−d2 +
(
2− ηr − η1
2
)
β,−d3 + (1− cη1)αT
}
(33)
Also,
V˙I
VI
=
(
2− ηr − η1
2
)
βI
VI
− d3 (34)
I˙
I
=
(1− cη1)αTVI
I
− d2 (35)
Then from (33) and (34), we get,
g6 ≤ I˙
I
− βI
VI
+ 2(1− cη1)αT +
(
ηr + η1
2
)
2βI
VI
+ max
{
−d2 +
(
2− ηr − η1
2
)
β,−d3 + (1− cη1)αT
}
(36)
From (27) and (35), we get,
g5 =
I˙
I
+ d2 − rT
k
− s
T
− d3 (37)
From (26),(36) and (37), we get,
µ(D) ≤ I˙
I
− βI
VI
+ 2(1− cη1)αT +
(
ηr + η1
2
)
2βI
VI
+ max
{
−d2 +
(
2− ηr − η1
2
)
β,−d3 + (1− cη1)αT
}
(38)
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From (25) and (38), we get,
g4 ≤ I˙
I
− βI
VI
+ (1− cη1)αV1 + 2(1− cη1)αT +
(
ηr + η1
2
)
2βI
VI
+ max
{
−d2 +
(
2− ηr − η1
2
)
β,−d3 + (1− cη1)αT
}
(39)
From (23), (24) and (39), we get,
µ(C) ≤ I˙
I
− βI
VI
+ (1− cη1)αV1 + 2(1− cη1)αT +
(
ηr + η1
2
)
2βI
VI
+ max
{
−d2 +
(
2− ηr − η1
2
)
β,−d3 + (1− cη1)αT
}
(40)
From (22) and (40), it follows
g2 ≤ I˙
I
− βI
VI
+ β + (1− cη1)αV1 + 2(1− cη1)αT +
(
ηr + η1
2
)
2βI
VI
+ max
{
−d2 +
(
2− ηr − η1
2
)
β,−d3 + (1− cη1)αT
}
(41)
From (21) and (35), we obtain
g1 =
I˙
I
− rT
k
− s
T
− (1− cη1)αVIT
I
+ (1− cη1)αT (42)
Therefore, we get
µ(B) ≤ I˙
I
− b for sufficiently large t. (43)
where
b =
βI
VI
− β − (1− cη1)αV1 − 2(1− cη1)αT −
(
ηr + η1
2
)
2βI
VI
− max
{
−d2 +
(
2− ηr − η1
2
)
β,−d3 + (1− cη1)αT
}
(44)
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Fig. 1 The figure shows the schematic diagram, explaining the dynamics of Hepatitis C virus
infection.
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Fig. 2 The figure shows the kinetics of viral decline in patients responding to interferon only,
which is characterized by biphasic graphs. The effect of ribavirin (ηr) is taken to be zero in
this case. Three biphasic decline has been shown for various drug efficiencies, of which, two
of them are greater than the critical drug efficiency ηc. All the parameter values are taken
from Table 1.
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Fig. 3 The figure shows that ribavirin has no role to play in reducing the viral load, when
the effectiveness of interferon is large. This is evident as viral load has not been altered when
compared to figure 2, where effectiveness of ribavirin is zero. All the parameter values are
taken from Table 1.
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Fig. 4 The figure shows the re-treatment of non-responders to a standard interferon regime,
which shows a first phase decline, followed by further minor decline during the second phase
and then a rebound of viral load, which are sometimes observed in patients. All the parameter
values are taken from Table 1.
0 5 10 15 20 25 30 35
102
103
104
105
106
107
108
Time (Days)
Vi
ra
l L
oa
d
η
c
= 0.745Start of
therapy
η
r
= 0.8
η
r
= 0.4
η
r
= 0.9
η1= 0.4
Fig. 5 The figure shows the biphasic decline of the viral load when the effectiveness of inter-
feron is small. All the parameter values are taken from Table 1.
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Fig. 6 The figure shows the dynamics of ribavirin monotherapy in the treatment of chronic
HCV. There is very little decline in the viral load, even with high doses of ribavirin. All the
parameter values are taken from Table 1.
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Fig. 7 The figure shows the viral kinetics after the therapy cessation. With different drug
efficiencies, the decline in viral load is observed from 0 to 14 days. After 14 days, the drug
efficiencies are set to zero and the virus resurges to pretreatment levels within (7-7.5) days of
post therapy cessation. All the parameter values are taken from Table 1.
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Fig. 8 The figure shows the dynamics of triphasic decline in the viral load. All the parameter
values are taken from Table 1.
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Fig. 9 The figure shows the effect of higher influx rates of new hepatocytes, where the triphasic
decline of viral load changes to biphasic decline. All the parameter values are taken from Table
1.
